GlassScriptPhysician profile
Haotong Wang
NPI 1710337399
$6,440.71
in general payments reported to CMS, 2019-2025
59 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.03 · 2020: $280 · 2022: $374 · 2023: $1,564 · 2024: $1,911 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,635 · Education: $78.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,634.73 |
| Education | $78.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $422.75 | 2019-2025 | |
| Janssen Biotech, INC. | $421.86 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $419.85 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $362.89 | 2020-2025 | Jakafi, Niktimvo, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $348.46 | 2023-2025 | Lynparza, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $317.31 | 2023-2025 | |
| Celgene Corporation | $294.29 | 2020-2025 | Reblozyl, Opdivo, Breyanzi |
| Astellas Pharma US INC | $253.31 | 2019-2025 | Vyloy, Xospata, Padcev |
| Rigel Pharmaceuticals, INC. | $202.56 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Merck Sharp & Dohme LLC | $197.18 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $194.47 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.51 | 2023-2025 | Iclusig, Fruzaqla, Ninlaro |
| Eisai INC. | $160.75 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.47 | 2023-2025 | Libtayo |
| Genzyme Corporation | $133.87 | 2023-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $130.42 | 2022-2023 | Kyprolis |
| Seagen INC. | $123.86 | 2022-2023 | Tukysa, Padcev |
| Sirtex Medical INC | $120.27 | 2024 | Sir-Spheres Microspheres |
| Emd Serono, INC. | $115.57 | 2022-2025 | Tepmetko, Bavencio |
| Taiho Oncology, INC. | $95.79 | 2023-2025 | |
| Genmab U.S., INC. | $87.05 | 2023-2025 | Epkinly |
| Array Biopharma INC | $85.49 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Bayer Healthcare Pharmaceuticals INC. | $80.21 | 2024-2025 | |
| Daiichi Sankyo INC. | $77.06 | 2025 | Enhertu, Datroway |
| Mirati Therapeutics, INC. | $75.95 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $71.95 | 2023-2025 | Xpovio |
| Glaxosmithkline, LLC. | $71.45 | 2023-2024 | Ojjaara |
| Kite Pharma, INC. | $71.28 | 2023-2025 | Yescarta |
| Sobi, INC | $69.14 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $64.52 | 2023-2025 | Ultomiris |
| Morphosys, US INC. | $61.22 | 2022-2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $58.54 | 2022-2025 | Onivyde, Somatuline Depot |
| Puma Biotechnology, INC. | $54.03 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $49.02 | 2023 | Imbruvica, Epkinly |
| Geron Corporation | $48.49 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $47.57 | 2024-2025 | Monoferric |
| Stemline Therapeutics INC. | $47.13 | 2024-2025 | Elzonris, Orserdu |
| Agios Pharmaceuticals, INC. | $46.65 | 2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $45.58 | 2023-2024 | Fotivda |
| Adaptive Biotechnologies Corporation | $44.77 | 2023-2024 | Clonoseq |
| Secura Bio, INC. | $43.77 | 2024 | Copiktra |
| Lilly USA, LLC | $42.74 | 2019-2022 | |
| Adc Therapeutics America, INC. | $40.00 | 2022-2024 | |
| Genentech USA, INC. | $39.22 | 2023-2025 | Venclexta, Polivy |
| Jazz Pharmaceuticals INC. | $38.46 | 2024 | |
| Apellis Pharmaceuticals, INC. | $36.94 | 2023 | |
| Legend Biotech USA INC. | $34.70 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $30.32 | 2023 | Qinlock |
| Foundation Medicine, INC. | $29.48 | 2023 | |
| Beigene USA, INC. | $26.50 | 2024 | Brukinsa |
| Tactile Systems Technology INC | $25.69 | 2023 | Entre Plus, Flexitouch Plus |
| Servier Pharmaceuticals LLC | $24.81 | 2025 | |
| Progenics Pharmaceuticals, INC. | $23.22 | 2025 | |
| Azurity Pharmaceuticals, INC. | $22.59 | 2025 | Danziten |
| Blueprint Medicines Corporation | $18.27 | 2024 | Ayvakit |
| Gilead Sciences, INC. | $18.11 | 2025 | Trodelvy |
| Exelixis INC. | $16.20 | 2023 | Cabometyx |
| Springworks Therapeutics, INC. | $15.29 | 2025 | Ogsiveo |
| Acrotech Biopharma INC. | $14.86 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haotong Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.